Good afternoon readers and welcome new subscribers.
We sent a momentum report at 9:35AM and GBSN turned into one of the biggest movers on the market!
Our emails landed from 9:35 to 9:37 and GBSN quickly started picking up momentum. From 9:37 to 9:40 GBSN traded from $2.20 to $2.50.
Like a coiled spring GBSN shot up to a high of $3.36 20 minutes later!
Did you catch a piece of the action? We are keeping our attention on GBSN into Monday in case the low float proves too small to keep up with demand!
Pending FDA decision, doubled sales, and a low float!
Here is a shortened version of this morning's report:
It should be exactly 9:35 if there were no email delays and we want you to add this company to the top of your Friday watchlist immediately.
Our Friday momentum play is GBSN - Great Basin Scientific Inc.
Yesterday, GBSN closed with a last price of $1.94
Great Basin Scientific, Inc., a molecular diagnostics company, develops and manufactures test kits and analyzers for a patented molecular diagnostic system.
GBSN has a relatively small float of 1.36M shares according to Finviz! Yahoo states 2.19M. That is extremely small for a Nasdaq (in our opinion) With around 5M shares outstanding, it's no wonder GBSN has already proved it can fly in the past! Not too long ago GBSN went on a massive one day tear from $2 all the way to $3.
GBSN just announced growing revenues for 2014:
For the 12 months ended December 31, 2014 revenue was $1.6M, an increase of 111.2% compared to $760K for the 12 months ended December 31, 2013.
In the fourth quarter of 2014, revenue was $445K, an increase of 50.5% compared to $295K in the fourth quarter of 2013.
FDA Approval Pending? Pending Catalyst.
"Normal" FDA decisions are typically for drugs. These are called PDUFA dates.
510(k) decisions are for medical devices, and GBSN could announce the results of their 510(k) submission any day now. Read this excerpt from their 2014 annual report:
In addition to our C. diff assay, we have developed a Group B Strep assay for which we filed a 510(k) submission to the FDA in the fourth quarter of 2014 and expect to receive the results of the FDA's review during the second quarter of 2015.
Will this new product boost revenue?
In the company's latest annual report, we came across another interesting excerpt.
As of December 31, 2014, we only have one commercial product, our C. diff assay and the average price has not materially changed since its commercial release.
We have 106 customers worldwide, who use an aggregate of 220 analyzers
We believe our revenue from the sale of our assays will increase as we expand our sales and marketing efforts and as we introduce new assays into the market.
We want all readers to glue GBSN to their watchlist immediately.
We believe the low float, 100% increase in revenues, and pending FDA decision warrant this ticker a TOP SPOT on our watchlist for the days ahead. Not only that, but if the company has just one product, and a second one gets approved, their sales could potentially end up even better than last year's 100% increase!
You can find tons of more info on the company's website.
Did you see GBSN move today?!
